Zika virus is a member of the flavivirus genus that had not been associated with severe disease in humans until the recent outbreaks, when it was linked to microcephaly in newborns in Brazil and to Guillain-Barré syndrome in adults in French Polynesia. Zika virus is related to dengue virus, and we report here that a category of antibodies isolated from dengue patients and targeting a conformational epitope potently neutralize Zika virus. The crystal structure of two of these antibodies in complex with the envelope protein of Zika virus reveals the details of a conserved epitope, which is also the site of interaction of the envelope protein dimer with the precursor prM protein during virus maturation. Comparison of the Zika and dengue virus immunocomplexes provides a lead for rational, epitope-focused design of a universal vaccine capable of eliciting potent cross-neutralizing antibodies to protect against Zika and dengue viruses simultaneously.

Nature doi: 10.1038/nature18938

Nature Latest Research

 
STRATEGIES FOR A COMPANY’S INTELLECTUAL PROPERTY. IP protection is a part of your business strategy and matches your commercial goals. A simple IP strategy is to protect your product and service by getting patent, trademark and copyright certificates.
 

U.S. COMPANY REGISTRATION. We help our foreign clients with registering U.S. business to support moving their innovations to U.S. market. We assist in navigating the process of setting up a new business and support while it grows.

EXHIBITION PRESENTATION. We are working with major organizers of international conferences in USA. We discuss in advance all possible discounts and available places for your expositions.